Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2008

01.02.2008 | Original Paper

Novel Biodegradable Stents for Benign Esophageal Strictures Following Endoscopic Submucosal Dissection

verfasst von: Yasuharu Saito, Toyohiko Tanaka, Akira Andoh, Hideki Minematsu, Kazunori Hata, Tomoyuki Tsujikawa, Norihisa Nitta, Kiyoshi Murata, Yoshihide Fujiyama

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The application of metallic stents for benign stenosis is limited due to long-term complications. We report here the results of the implantation of a novel biodegradable poly-l-lactic acid (PLLA) esophageal stent in two patients with benign esophageal stenosis after endoscopic submucosal dissection (ESD). Case 1 was a 64-year-old man who received ESD for an early squamous esophageal cancer in the middle esophagus. The mucosal defect was seven-eighths of the circumference, and the distal margin of the resection scar formed the stenosis. After balloon dilatation, the PLLA esophageal stent was endoscopically placed; for 6 months, he has not experienced any symptoms of re-stenosis. Case 2 consisted of a 62-year-old man who developed an early squamous esophageal cancer in the middle esophagus. The lesion was resected by ESD, and the mucosal defect was seven-eighths of the circumference. The resection scar formed the stenosis, and the PLLA esophageal stent was endoscopically placed. He also has not experienced any symptoms of re-stenosis for 6 months. In conclusion, the PLLA esophageal stent provides a new possibility for the management of benign esophageal strictures after ESD. Due to the biodegradable features of this stent, longer term studies are necessary to investigate the relationship between the expected disappearance of the stent and the patency of the stricture.
Literatur
1.
Zurück zum Zitat Holt AP, Patel M, Ahmed MM (2004) Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc 60:1010–1017PubMedCrossRef Holt AP, Patel M, Ahmed MM (2004) Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc 60:1010–1017PubMedCrossRef
2.
Zurück zum Zitat Song HY, Do YS, Han YM, Sung KB, Choi EK, Sohn KH, Kim HR, Kim SH, Min YI (1994) Covered, expandable esophageal metallic stent tubes: experiences in 119 patients. Radiology 193:689–695PubMed Song HY, Do YS, Han YM, Sung KB, Choi EK, Sohn KH, Kim HR, Kim SH, Min YI (1994) Covered, expandable esophageal metallic stent tubes: experiences in 119 patients. Radiology 193:689–695PubMed
3.
Zurück zum Zitat Song HY, Park SI, Do YS, Yoon HK, Sung KB, Sohn KH, Min YI (1997) Expandable metallic stent placement in patients with benign esophageal strictures: results of long-term follow-up. Radiology 203:131–136PubMed Song HY, Park SI, Do YS, Yoon HK, Sung KB, Sohn KH, Min YI (1997) Expandable metallic stent placement in patients with benign esophageal strictures: results of long-term follow-up. Radiology 203:131–136PubMed
4.
Zurück zum Zitat Ackroyd R, Watson DI, Devitt PG, Jamieson GG (2001) Expandable metallic stents should not be used in the treatment of benign esophageal strictures. J Gastroenterol Hepatol 16:484–487PubMedCrossRef Ackroyd R, Watson DI, Devitt PG, Jamieson GG (2001) Expandable metallic stents should not be used in the treatment of benign esophageal strictures. J Gastroenterol Hepatol 16:484–487PubMedCrossRef
5.
Zurück zum Zitat Evrard S, Le Moine O, Lazaraki G, Dormann A, El Nakadi I, Deviere J (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60:894–900PubMedCrossRef Evrard S, Le Moine O, Lazaraki G, Dormann A, El Nakadi I, Deviere J (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60:894–900PubMedCrossRef
6.
Zurück zum Zitat Mercer CD, Hill LD (1986) Surgical management of peptic esophageal stricture. Twenty-year experience. J Thorac Cardiovasc Surg 91:371–378PubMed Mercer CD, Hill LD (1986) Surgical management of peptic esophageal stricture. Twenty-year experience. J Thorac Cardiovasc Surg 91:371–378PubMed
7.
Zurück zum Zitat Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB 3rd (1992) Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20:467–474PubMedCrossRef Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB 3rd (1992) Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20:467–474PubMedCrossRef
8.
Zurück zum Zitat Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M, Miyata Y (2005) Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3:S67–S70 PubMedCrossRef Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M, Miyata Y (2005) Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3:S67–S70 PubMedCrossRef
9.
Zurück zum Zitat Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch Surg 93:839–843PubMed Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch Surg 93:839–843PubMed
10.
Zurück zum Zitat Schakenraad JM, Dijkstra PJ (1991) Biocompatibility of poly (dl-lactic acid/glycine) copolymers. Clin Mater 7:253–269PubMedCrossRef Schakenraad JM, Dijkstra PJ (1991) Biocompatibility of poly (dl-lactic acid/glycine) copolymers. Clin Mater 7:253–269PubMedCrossRef
11.
Zurück zum Zitat Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P (1990) Enzymatic activity toward poly(l-lactic acid) implants. J Biomed Mater Res 24:529–545PubMedCrossRef Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P (1990) Enzymatic activity toward poly(l-lactic acid) implants. J Biomed Mater Res 24:529–545PubMedCrossRef
12.
Zurück zum Zitat Bostman OM (1991) Absorbable implants for the fixation of fractures. J Bone Joint Surg Am 73:148–153PubMed Bostman OM (1991) Absorbable implants for the fixation of fractures. J Bone Joint Surg Am 73:148–153PubMed
13.
Zurück zum Zitat Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404PubMed Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404PubMed
14.
Zurück zum Zitat Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Okada M, Nakamura T, Komori H, Motohara S, Uehata H (2001) Biodegradable polymeric stents. Curr Interv Cardiol Rep 3:10–17PubMedCrossRef Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Okada M, Nakamura T, Komori H, Motohara S, Uehata H (2001) Biodegradable polymeric stents. Curr Interv Cardiol Rep 3:10–17PubMedCrossRef
15.
Zurück zum Zitat Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, von Dahl J, Bosserhoff AK, Michaeli W, Hanrath P, Weber C, Blindt R (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340PubMedCrossRef Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, von Dahl J, Bosserhoff AK, Michaeli W, Hanrath P, Weber C, Blindt R (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340PubMedCrossRef
16.
Zurück zum Zitat Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780–786PubMedCrossRef Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780–786PubMedCrossRef
17.
Zurück zum Zitat Robey TC, Eiselt PM, Murphy HS, Mooney DJ, Weatherly RA (2000) Biodegradable external tracheal stents and their use in a rabbit tracheal reconstruction model. Laryngoscope 110:1936–1942PubMedCrossRef Robey TC, Eiselt PM, Murphy HS, Mooney DJ, Weatherly RA (2000) Biodegradable external tracheal stents and their use in a rabbit tracheal reconstruction model. Laryngoscope 110:1936–1942PubMedCrossRef
18.
Zurück zum Zitat Chepurov AK, Krivoborodov GG, Zubarev AV, Zaitsev NV, Markina N (2003) Biodegradable ureteral stents in treating patients with infravesical obstruction. Urologiia 44–50 Chepurov AK, Krivoborodov GG, Zubarev AV, Zaitsev NV, Markina N (2003) Biodegradable ureteral stents in treating patients with infravesical obstruction. Urologiia 44–50
19.
Zurück zum Zitat Knutson T, Pettersson S, Dahlstrand C (2002) The use of biodegradable PGA stents to judge the risk of post-TURP incontinence in patients with combined bladder outlet obstruction and overactive bladder. Eur Urol 42:262–267PubMedCrossRef Knutson T, Pettersson S, Dahlstrand C (2002) The use of biodegradable PGA stents to judge the risk of post-TURP incontinence in patients with combined bladder outlet obstruction and overactive bladder. Eur Urol 42:262–267PubMedCrossRef
Metadaten
Titel
Novel Biodegradable Stents for Benign Esophageal Strictures Following Endoscopic Submucosal Dissection
verfasst von
Yasuharu Saito
Toyohiko Tanaka
Akira Andoh
Hideki Minematsu
Kazunori Hata
Tomoyuki Tsujikawa
Norihisa Nitta
Kiyoshi Murata
Yoshihide Fujiyama
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2008
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9873-6

Weitere Artikel der Ausgabe 2/2008

Digestive Diseases and Sciences 2/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.